{"product_id":"scripps-clinical-hematology-and-oncology-2025","title":"Scripps Clinical Hematology and Oncology 2025","description":"\u003ch1 class=\"product_title entry-title\"\u003eScripps Clinical Hematology and Oncology 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Include: 41 videos + 1 pdf, size: 22.73 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: hematologists, oncologists, internists, advanced practice providers, and trainees\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eClinical Hematology \u0026amp; Oncology Presented by Scripps Cancer Center\u003cbr\u003e\u003cbr\u003eFEBRUARY 15-17, 2025 Hyatt Regency La Jolla at Aventine • San Diego, CA\u003cbr\u003e\u003cbr\u003eThe Scripps Cancer Center’s Clinical Hematology and Oncology conference is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances. Our annual program is a nationally accredited continuing medical education conference and is one of the largest annual hematology\/oncology meeting held in the West, among others such as ASH, ASCO and the San Antonio Breast Meeting. This conference is one of the few that combines topics in both hematology and oncology.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eAfter attending this live activity, participants should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eDescribe the clinical and molecular facets of pathogenesis, diagnostic approaches, and therapeutic modalities available for various hematologic disorders.\u003c\/li\u003e\n\u003cli\u003eSelect and apply the changing approaches to hematologic malignancies, particularly as they relate to evidence-based standards of care, including innovations in diagnosis and treatment.\u003c\/li\u003e\n\u003cli\u003eChoose new therapeutic options for the treatment of several common malignancies, understanding appropriate indications and contraindications to these therapeutic approaches.\u003c\/li\u003e\n\u003cli\u003eIntegrate evolving approaches to solid tumors and breast cancer from both a diagnostic, prognostic, and therapeutic perspective.\u003c\/li\u003e\n\u003cli\u003eApply practical expertise gained from the clinical situations discussed in the panel sessions with an emphasis on data-based approaches to patients with common, but serious hematology oncology conditions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThe Scripps \u003cem\u003eClinical Hematology and Oncology Conference 2025\u003c\/em\u003e is best for hematologists, oncologists, internists, advanced practice providers, and trainees who want CME‑accredited, expert‑led updates on the latest therapies, diagnostics, and multidisciplinary management strategies in cancer and blood disorders.\u003cbr\u003e\u003ch3\u003e\n\u003cimg alt=\"👩‍⚕️\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f469-200d-2695-fe0f.svg?v=1770211927\"\u003e Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eMedical oncologists and hematologists managing patients with solid tumors, leukemias, lymphomas, and other blood disorders.\u003c\/li\u003e\n\u003cli\u003eInternal medicine physicians and subspecialists who co‑manage cancer patients or encounter hematologic issues in practice.\u003c\/li\u003e\n\u003cli\u003eAdvanced practice providers (NPs, PAs, CNSs) working in oncology and hematology clinics.\u003c\/li\u003e\n\u003cli\u003eResidents and fellows in hematology\/oncology training programs preparing for board exams or subspecialty practice.\u003c\/li\u003e\n\u003cli\u003eOncology nurses and pharmacists involved in cancer care delivery and supportive therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\n\u003cimg alt=\"📚\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f4da.svg?v=1770211931\"\u003e What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLatest clinical trial data and FDA approvals in hematology and oncology.\u003c\/li\u003e\n\u003cli\u003eUpdates in immunotherapy, targeted therapy, and cellular therapies (CAR‑T, bispecifics).\u003c\/li\u003e\n\u003cli\u003eBest practices in supportive care: symptom management, survivorship, and toxicity mitigation.\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary approaches to cancer care, integrating surgery, radiation, and systemic therapy.\u003c\/li\u003e\n\u003cli\u003eCase‑based discussions highlighting diagnostic and therapeutic challenges.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eSaturday, February 15, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Educational Overview\u003c\/li\u003e\n\u003cli\u003e8 a.m. Peri-operative Thrombocytopenia Ted Warkentin, MD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Hormonal Therapy and Thrombosis Risk Damon Houghton, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Barely Abnormal CBCs Alice Ma, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:15 a.m. Antiphospholipid Syndrome: 2024 Update Stephan Moll, MD\u003c\/li\u003e\n\u003cli\u003e10:45 a.m. Hypereosinophilic Syndrome Jason Gotlib, MD\u003c\/li\u003e\n\u003cli\u003e11:15 a.m. Investigating Bleeding of an Obscure Cause Menaka Pai, MD\u003c\/li\u003e\n\u003cli\u003e11:45 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eNoon Lunch Noon Non-CME Lunch Symposium Hosted by Agios Pharmaceuticals Noon Non-CME Lunch Symposium Hosted by AstraZeneca\u003c\/li\u003e\n\u003cli\u003e1 p.m. What’s New in AML TBD\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Should Patients Still Undergo BMT for Myeloma? Morie Gertz, MD\u003c\/li\u003e\n\u003cli\u003e2 p.m. Evolving Therapeutic Approaches in Patients with Low-risk MDS Aref Al-Kali, MD\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e2:45 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3:15 p.m. Clinical Updates in B-ALL Wendy Stock, MD\u003c\/li\u003e\n\u003cli\u003e3:45 p.m. Refractory Diffuse Large Cell Lymphoma Stephen Schuster, MD\u003c\/li\u003e\n\u003cli\u003e4:15 p.m. HLH and HLH-like Inflammatory Syndromes TBD\u003c\/li\u003e\n\u003cli\u003e4:45 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eCONCURRENT BREAKOUT SESSIONS 5:15 p.m.\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eBreakout #1: Interesting Cases in Thrombosis Stephan Moll, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #2: Interesting Cases in Thrombocytopenia Ted Warkentin, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #3: Interesting Cases in Bleeding Alice Ma, MD\u003c\/li\u003e\n\u003cli\u003eBreakout #4: Interesting Cases in Plasma Cell Dyscrasias Morie Gertz, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e6:15 p.m. Adjourn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eSunday, February 16, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Ultra Low Her2 Breast Cancer: Pushing the Boundary in IHC 0 and Treatment Implications TBD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Changing Landscape of Sequencing in HR Positive, Her2 Negative Metastatic Breast Cancer Aditya Bardia, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Sequencing Therapies in Early Triple Negative Breast Cancer Laura Huppert, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Neoadjuvant and Adjuvant Therapy for Melanoma TBD\u003c\/li\u003e\n\u003cli\u003e11 a.m. Management of Variant Histology Renal Cell Carcinoma Sumanta Pal, MD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Targeted Therapies in Central Nervous System Metastasis TBD\u003c\/li\u003e\n\u003cli\u003eNoon Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Lunch\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Non-CME Lunch Symposium Hosted by Lilly\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Rectal Cancer—Making Sense of TNT, ctDNA, and Surgery: A Case-based, Multidisciplinary Discussion Michael Overman, MD—Medical Oncology Brian Bednarski, MD—Rectal Surgery Eugene Koay, MD—Radiation Oncology\u003c\/li\u003e\n\u003cli\u003e3 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e3:30 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e4 p.m. New Targeted Therapies for Gastroesophageal Cancer TBD\u003c\/li\u003e\n\u003cli\u003e4:30 p.m. Updates in Neuroendocrine Tumors Jonathan Strosberg, MD\u003c\/li\u003e\n\u003cli\u003e5 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e5:30 p.m. Adjourn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003eMonday, February 17, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e7 a.m. Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Announcements\u003c\/li\u003e\n\u003cli\u003e8 a.m. Role of Immune Therapy in Advanced Endometrial Cancer Ramez Eskander, MD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Updates in the Treatment of Metastatic Soft Tissue Sarcoma Mark Agulnik, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Genomic Risk Stratification and High Sensitivity Imaging in Localized Prostate Cancer Tanya Barauskas Dorff, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e10 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:30 a.m. Optimal Management of ALK Rearranged NSCLC Kamya Sankar, MD\u003c\/li\u003e\n\u003cli\u003e11 a.m. Evidence-Based Management of Hormone Deprivation Symptoms After Cancer TBD\u003c\/li\u003e\n\u003cli\u003e11:30 a.m. Management of Common Skin-related Side Effects of Cancer Treatment TBD\u003c\/li\u003e\n\u003cli\u003eNoon Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e12:30 p.m. Final Adjournment Topics, times, and speakers are subject to change.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954515284066,"sku":"MED-AMB05152","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Scripps-Clinical-Hematology-and-Oncology-2025.webp?v=1779378721","url":"https:\/\/meducourse.com\/products\/scripps-clinical-hematology-and-oncology-2025","provider":"Meducourse","version":"1.0","type":"link"}